On July 16, UnitedHealth jumped 8.3% in morning trading. The stock surged following the release of stronger-than-expected second-quarter results.

UnitedHealth reported Q2 adjusted EPS of $6.38, beating the analyst consensus estimate of $4.86 by 31.28%, and representing a 56.37% year-over-year increase from $4.08 per share in the same period last year. Revenue came in at $112.032 billion, surpassing the $110.825 billion estimate. The results decisively dispelled pre-earnings concerns that had weighed on the managed care sector, which saw broad-based selling the previous session.

Heading into the report, multiple Wall Street firms had raised price targets, including Wells Fargo to $485, Piper Sandler and KeyBanc to $475, and Evercore ISI to $480, all maintaining overweight or equivalent ratings. BofA Securities had upgraded the stock to Buy in early June, citing improving medical cost trends. The strong beat validates the bull thesis that utilization trends and cost management are tracking favorably, reinforcing sector-wide optimism as peers Humana rose 3.78% and Centene gained 2.84%.

UnitedHealth raised its ​2026 profit forecast, as the company had a better handle on medical costs and improved operating income in its Optum health ‌services business.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)